Prevalence and Resistance Profiles of Vancomycin-resistant Enterococcal Isolates in Iran; An Eight-month Report from Nine Major Cities.

Abstract

Enterococcal infections comprise a wide range of diseases with increasing importance due to the growing frequency of health-care-associated infections and the increasing incidence of antimicrobial resistance. Vancomycin-resistant Enterococcus (VRE) is an emerging drug-resistant organism responsible for increasing numbers of nosocomial infections in both adults and children. Few data are available on the epidemiology and impact of VRE infections in Iranians. In the present study, attempts were made to evaluate the prevalence and molecular characterization of VRE isolates from patients referred to several hospitals in Iran. Eight hundred and fourteen enterococcal clinical isolates from different patients were selected for this cross-sectional study during June 2018 and February 2019. Antimicrobial susceptibility testing was performed by standard methods according to the Clinical Laboratories Standards Institute (CLSI) guidelines. The vanA and vanB genes in VRE isolates were amplified by PCR. Our findings indicated that 20.7% of the isolates were collected from hospitalized patients in the ICU. Among all the isolates, 254 (30%) were identified as VRE strains. All of the VRE isolates were sensitive to linezolid. Moreover, only 39.9% of the VRE isolates harbored the vanA gene, while none of them carried the vanB gene. The present study reports the highest range of VRE infections in Iran. The constant surveillance and monitoring of VRE strains are recommended to limit the occurrence and spread of VRE clones within and among hospitals and community settings.